bispecific antibodies

Looking forward to ASH 2021: key updates in multiple myeloma 1:03
Looking forward to ASH 2021: key updates in multiple myeloma
Samir N. Parekh • 10 Nov 2021
Moving CAR T-cell therapy and bispecific antibodies in the consolidation setting 1:25
Moving CAR T-cell therapy and bispecific antibodies in the consolidation setting
Ruben Niesvizky • 25 Oct 2021
Bispecific antibodies vs CAR T-cells for R/R multiple myeloma 4:35
Bispecific antibodies vs CAR T-cells for R/R multiple myeloma
Hermann Einsele • 12 Oct 2021
The role of allo-transplant for patients with ALL 3:23
The role of allo-transplant for patients with ALL
Mohamad Mohty • 4 Oct 2021
The potential of CAR-T therapy in MCL 1:56
The potential of CAR-T therapy in MCL
Michael Wang • 31 Aug 2021
Advances in the use of bispecific antibodies for the treatment of CLL 5:20
Advances in the use of bispecific antibodies for the treatment of CLL
Adrian Wiestner • 20 Sep 2021
Talquetamab, cevostamab and CAR-T in the future treatment of myeloma 3:22
Talquetamab, cevostamab and CAR-T in the future treatment of myeloma
Luciano Costa • 6 Sep 2021
Long-term disease-free survival in myeloma 1:59
Long-term disease-free survival in myeloma
Heinz Ludwig et al. • 9 Sep 2021
The new era of myeloma therapies 2:30
The new era of myeloma therapies
Irene Ghobrial et al. • 10 Sep 2021
BCMA-targeted BiTEs for multiple myeloma 8:13
BCMA-targeted BiTEs for multiple myeloma
Niels van de Donk • 10 Sep 2021
Sequencing BCMA-targeted therapies in myeloma 1:29
Sequencing BCMA-targeted therapies in myeloma
Niels van de Donk • 10 Sep 2021
Updates on immunotherapies for myeloma at IMW 2021 2:57
Updates on immunotherapies for myeloma at IMW 2021
Philippe Moreau • 10 Sep 2021
CAR-T vs bispecifics: the best immune approach to replace ASCT 6:40
CAR-T vs bispecifics: the best immune approach to replace ASCT
Hermann Einsele • 3 Sep 2021
Replacing ASCT: CAR-T or bispecific antibodies? 2:52
Replacing ASCT: CAR-T or bispecific antibodies?
Parameswaran Hari • 2 Sep 2021
The current and future ADC treatment landscape for lymphoma 9:09
The current and future ADC treatment landscape for lymphoma
Nilanjan Ghosh • 24 Jun 2021
The antibody treatment landscape in myeloma 1:28
The antibody treatment landscape in myeloma
Sagar Lonial • 9 Jun 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals